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W ith the completion of the Human Genome Project in 2003, the world's attention has 
focused on converting this vast store­
house of information into innovative 
health care solutions. The ultimate 
promise, assuming we know everyone's 
genotype, is to ensure that every person 
has op t imum health throughout his/her 
life. This promise has many parts, 
including opt imum nutrition, clean air 
and water supplies, up-to-date immu­
nizations and regular health screenings. 
The part of the promise to be fulfilled 
by knowledge and information stem­
ming from genomics, proteomics and 
other "omics" is yet unfolding, but the 
first cautious steps are being taken and 
are called "Personalized Medicine". 
Personalized Medicine implies that op­
timum health goes beyond the basics of 
clean air and water and takes advantage 
of the "omics" knowledge to allow the 
person and his/her clinicians to make 
therapeutic and lifestyle choices which 
take the "omics" into account. 
Personalized Medicine does not 
have a crisp definition, but rather re­
flects a broad coalition of ideas brought 
to bear on the age-old notion of per­
sonalized care. The proud tradition of 
health care is to focus on every patient 
and to provide care that is cognizant 
of the person's individual situation and 
values, but the situation rarely includes 
specific genetic/genomic information. 
The Personalized Medicine move­
ment incorporates the use of molecular 
analyses and methods evolving from 
knowledge of genomics to better man­
age a patient's disease or predisposition 
toward a disease. In the Genomics and 
Personalized Medicine Act of 2006 ' , 
personalized medicine is defined as "... 
the application of genomic and molecu­
lar data to better target the delivery of 
health care, facilitate the discovery and 
clinical testing of new products, and 
help determine a patient's predisposition 
to a particular disease or condition". The 
belief of the scientific and health-care 
community is that knowledge of ge­
nomics will contribute to better health 
outcomes. The specific approaches are 
not yet fully developed but will include 
genetic/genomic screening programs, 
genetic/genomic risk analyses, and 
the use of diagnostic and therapeutic 
modalities that are still evolving but will 
certainly involve micro-arrays and other 
high-throughput analyses in addition to 
standard genetic tests. 
While Personalized Medicine 
ultimately aims to adapt therapies to in­
dividual patients, the initial solution will 
divide patients into groups by genetic 
and other markers that predict disease 
progression and treatment outcomes. 
In this scenario, pharmacogenetics is at 
the center of the research and prac­
tice. Pharmacogenetics gives a partial 
explanation to the different responses 
of individuals to the same drugs. For 
example, the genetic variants for two 
genes (CYP2C9 and VKORC1) along 
with other patient data can explain a 
substantial portion of the variability 
seen in a person's response to Warfarin, 
a powerful and frequently prescribed 
anticoagulant'. The hope in the case of 
Warfarin is that the adverse drug reac­
tions of excessive bleeding or clotting 
can be minimized by genetic testing 
to help predict in advance what is the 
optimal dose for a specific patient. 
Genomic, proteomic or functional 
genomic biomarkers (features that are 
associated with the course of a disease) 
can help to define subtypes of diseases 
such as cancers that have previously been 
treated as single entities. This reclassifica­
tion leads to new diagnostic and therapeu­
tic procedures that hopefully can be shown 
to be cost effective and efficacious. One 
success story is the targeted use of genetic 
testing for mutations in the EGFR gene to 
determine which group of patients will be 
responsive to gefitinib as a treatment for 
non-small cell lung cancer1. Obviously this 
trend in health care has the potential to 
shift costs because of the increased use of 
expensive tests, but also has the potential 
to significantly improve outcomes and 
to avoid expensive treatment for those 
individuals who can be shown to have a 
non-responsive genotype. 
Every component of the scientific 
community will play a part in making 
the promise of Personalized Medicine 
a reality, but the field of Biomedical 
Informatics is especially critical to 
making the vision come alive. The 
enormous quantity of complex data poses 
a daunting challenge to the use of this 
data in our traditional healthcare system. 
Biomedical Informatics is a field that 
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specializes in analyses of such data and 
the development of techniques to bring 
focused information out of the data sets. 
Almost 1000 public biological databases 
are available to researchers and health 
professionals with data on genomes, 
proteomes, metabolomes, etc, and can be 
used for basic data and as reference sets. 
Almost 1400 genetic tests associated with 
diseases [http://www.genetests.org] can 
be ordered by any healthcare practitio­
ner (some tests can even be ordered by 
individuals over the internet without 
going through their physicians); there are 
over 20,000 genes and so the number of 
new genetic tests will continue to grow. 
This enormous quantity of information 
could be brought into play for a single 
individual if the cost of a full genome se­
quence were affordable and the scientific 
and healthcare community understood 
the implications of the results of such a 
large battery of genetic tests. But we are 
a long way from this. The cost for a full 
genome analysis is prohibitive at this 
time and will be for the next decade or 
so, although the N I H is giving grants to 
individuals who can work toward a full-
genome sequence test for S1000. 
It will take quite some time to 
create a synthesis of all of the genes 
and proteins and regulatory elements 
for any specific human, and it will take 
a very long time to make this synthe­
sis understandable to all concerned. 
It is likely that the result will be a set 
of probabilities and risks for specific 
healthcare problems, a set of lifestyle 
recommendations (for example, avoid 
smoking if you have the Z allele of the 
SERPINA1 gene), and an expanding 
list of diagnostic tests and therapies. The 
recommendations will almost certainly 
include a set of medications that the 
person should avoid and another set of 
medications that would be more appro­
priate for his/her use; all of this would 
be based on both personal genomics and 
family history as well as the data from 
other tests and healthcare experiences, 
likely pulled from an analysis of data in 
the Electronic Medical Record (EMR). 
The brave new world of 
Personalized Medicine is slowly emerg­
ing, but the complexities of the situation 
mean that the full blossoming will take 
years to arrive. To use this data effectively, 
the worldwide community must define 
semantic and logical standards that rep­
resent genotype-phenotype data so they 
can exchange information reliably about 
genetics, patients and health conditions. 
The understanding of the implications 
of specific tests is moving so rapidly that 
there needs to be a set of guidelines that 
are updated regularly and are readily avail­
able from a trusted source. Health care 
providers cannot be expected to memorize 
recommendations for the permutations of 
this large data set, and so it makes sense 
that computer systems will be called into 
play. Ultimately the genomic (and other 
omics) information on a patient would 
be linked to or stored as a component of 
the Electronic Medical Record. Decision 
support systems acting upon standard de­
fined data items and guideline or protocol 
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algorithms would process the data and dy­
namically send alerts or recommendations 
to the health care providers. The patients 
would have access to their lifetime medi­
cal data and the same recommendations 
and reminders via a Personalized Health 
Record. The public would have access 
to systems on the Internet to explain the 
implications of various diseases, risks and 
tests in a language that was understand­
able. The Genetics Home Reference 
[http://www.ghr.nlm.nih.gov] was created 
by the National Library of Medicine 
specifically to help consumers navigate 
through the complex issues of genetic 
disorders from patient questions to the 
specifics of research data 4. 
The University of Utah has exper­
tise and resources that promise many 
contributions for the journey towards 
Personalized Medicine. There are many 
sources of data that will assist in defin­
ing genes associated with specific health 
problems. In fact, more single disease 
genes have already been discovered at 
the University of Utah than at any other 
university in the world, based, in part, 
on the use of its rich databases like the 
Utah Population Data Base (UPDB) to 
assist in finding gene-disease associa­
tions. There is a long and rich history of 
working with EMR's in the Department 
of Biomedical Informatics. There is a 
great potential for new pharmaceuti­
cals and therapies based on the specific 
knowledge and definitions of biomark-
ers being developed. Most importantly, 
the scientists and healthcare professionals 
have a spirit of collaboration and find joy 
in working in multidisciplinary teams, 
an essential component for climbing this 
new scientific mountain. The knowledge 
of genetics, genomics, proteomics, and 
other "omics" alone cannot transform 
healthcare. Research on biomarkers has 
signaled molecular profiling as promis­
ing, but biomarkers with adequate 
specificity and sensitivity are still scarce 
for most diseases. To achieve the dream 
of Personalized Medicine, heterogeneous 
clinical and genomic data sources must 
be integrated into a scientifically mean­
ingful and productive system. The results 
must be focused specifically on individu­
als throughout their lives, in sickness and 
in health. Then the vision of Personalized 
Medicine will become a reality. 
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